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Abstract
Background—Folate, vitamin B6, vitamin B12, and methionine are involved in DNA synthesis 
and methylation and thus may modulate pancreatic cancer risk. We investigated these associations 
in a population-based case-control study conducted in 1994–1998.
Methods—Cases (n=150) were identified from all hospitals in the metropolitan areas of the Twin 
Cities and the Mayo Clinic, Minnesota. Controls (n=459) were selected randomly from the general 
population and were frequency matched to cases by age, sex, and race. Logistic regression was 
used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for risk of pancreatic 
cancer in relation to intake of nutrients considered.
Results—Dietary intake of folate was associated with a reduced pancreatic cancer risk [OR (95% 
CI) for quartile (Q) 4 vs. Q1: 0.31 (0.12–0.78)]. A composite score (range from 2 to 8), reflecting 
combined dietary intake of folate and vitamin B6, was also inversely associated with pancreatic 
cancer risk [OR (95% CI) for Q4 vs. Q1: 0.24 (0.08–0.70)]. Null associations were found for 
intake of vitamin B12 and methionine.
Conclusions—Dietary folate intake was associated with a reduced pancreatic cancer risk, and 
this association became stronger when dietary intake of folate and vitamin B6 was combined in 
analysis.
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Introduction
Pancreatic cancer is one of the deadliest cancers primarily because it lacks an effective 
screening test and is usually diagnosed at an advanced stage (1, 2). The 5-year survival rate 
is only 8.2% in the U.S. (3). In 2017, there were an estimated 53,670 cases of pancreatic 
cancer and 43,090 deaths from this disease in the U.S. (4). Despite advances in medical 
treatment, pancreatic cancer mortality rates in the U.S. have continued to climb in recent 
years (5). Therefore, primary prevention remains a top priority for reducing the burden of 
pancreatic cancer. To achieve this goal, it is necessary to elucidate its largely unknown 
etiology.
Diet may play a role in the etiology of pancreatic cancer (6). It is estimated that 30–50% of 
pancreatic cancer cases are attributable to dietary factors or practices (7). Of potential 
significance to pancreatic cancer risk are dietary nutrients involved in methyl-group 
metabolism, including folate, vitamin B6 (pyridoxine), vitamin B12 (cobalamin), and 
methionine. Folate participates in the conversion of homocysteine to methionine, a 
biochemical reaction catalyzed by methionine synthase that has vitamin B12 as a cofactor (8, 
9). As an essential amino acid in the human diet, methionine serves as a methyl-group donor 
in the form of S-adenosylmethionine. Vitamin B6 is a cofactor for multiple critical enzymes 
in the methyl-group metabolism pathway (10). Given that all these nutrients are required in 
DNA synthesis and methylation (11), it is possible that they are implicated in the etiology of 
pancreatic cancer. This hypothesis has gained support from experimental studies that 
revealed frequently aberrant DNA methylation in some pancreatic tumors and cancer cell 
lines (12, 13).
Despite the biological plausibility, the associations between intake of nutrients involved in 
methyl-group availability and the risk of pancreatic cancer have been inconsistent across 
previous studies, with both inverse and null associations reported (14–18). The present 
analysis was thus conducted to investigate the associations between dietary and 
supplementary intake of folate, vitamin B6, vitamin B12, and methionine and the risk of 
pancreatic cancer in a population-based case-control study in Minnesota.
Materials and Methods
Study Population
A population-based case-control study of pancreatic cancer was conducted in Minnesota 
from April 1994 to September 1998, and its design and methodology have been described in 
detail elsewhere (19, 20). Briefly, this study was based in the Upper Midwestern United 
States and the cases were recruited from all hospitals in the Minneapolis and St. Paul 
metropolitan areas in Minnesota and the Mayo Clinic, Rochester, Minnesota. Cases enrolled 
from the Mayo Clinic were restricted to residents in the Upper Midwest. Cases were patients 
with a recent diagnosis of pathologically-confirmed pancreatic cancer (International 
Classification of Disease for Oncology, 3rd edition, code C25). To be eligible, the patients 
had to be at least 20 years of age, proficient in English, and mentally competent. As many 
pancreatic cancer patients die quickly after diagnosis, a rapid case recruitment procedure 
was employed to recruit cases, resulting in a median number of 13 days between diagnosis 
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and first contact for enrolled cases. A total of 460 identified cases met the eligibility criteria. 
Of these, 85 did not participate due to death prior to being contacted or interviewed, 79 
refused participation, 31 were disallowed by their physician, and 7 could not be reached or 
contacted. After these exclusions (n = 202 in total), 258 cases participated in the study, 
yielding a response rate of 56%.
Controls were selected randomly from the same metropolitan areas of Minneapolis and St. 
Paul, Minnesota. Controls between 20 and 64 years of age were identified from a database 
of drivers’ licenses and state identity cards. Controls of at least 65 years of age were found 
in the database of the Centers for Medicare and Medicaid Services. Controls had the same 
inclusion criteria as cases, disallowing pancreatic cancer diagnosis. Frequency matching was 
used to match controls to cases by age (within 5 years), sex, and race. Of 1,141 eligible 
controls ascertained, 676 chose to participate in the study, resulting in a response rate of 
59%.
Data on diet and alcohol consumption were not available from 108 cases and 217 controls 
primarily due to the frailty of cases to endure the interview process or controls declining to 
complete the food frequency questionnaire (FFQ). In total, 150 cases and 459 controls 
provided the data for the present analysis.
Data Collection
The University of Minnesota and the Mayo Clinic institutional review boards approved the 
study protocol, and written informed consent was collected from all study participants 
before the interview. A general questionnaire was used to solicit data on demographic 
characteristics (e.g. age, sex, and race), socioeconomic factors (e.g. education), and lifestyle 
factors (e.g. status, amount, and duration of cigarette smoking, intensity and duration of 
physical activity) as well as personal history of disease (e.g. diabetes). The usual diet of 
study subjects was assessed with a slightly modified version of the Willett FFQ (21). 
Validation studies have shown that the Willett FFQ offers reasonable levels of 
reproducibility and validity (against dietary records) for intakes of nutrients and individual 
foods (21, 22). Both the general questionnaire and FFQ were administered by trained 
research staff during in-person interviews.
The FFQ used in this case-control study is composed of 153 individual foods or food groups 
(including alcohol consumption) commonly consumed in the U.S. During the interview, 
subjects recalled how frequently they consumed each of the food items listed in the FFQ in 
the year preceding pancreatic cancer diagnosis for cases or in the previous year for controls. 
Energy and nutrient intake was calculated by multiplying the pre-specified portion size 
amount in each food item by the recalled frequency of consumption and summed over all 
food items. The Minnesota Colon Cancer Prevention Research Unit Studies database was 
employed to estimate the amounts of energy and nutrients contained in portion sizes of all 
food items included in the FFQ used. In the present study, the nutrients evaluated in relation 
to pancreatic cancer risk are folate, vitamin B6, vitamin B12, and methionine. Data on both 
dietary and supplemental sources of all these nutrients (except methionine) were available 
for analysis.
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Statistical Analysis
Cases and controls were compared for differences in age, sex, race, education, cigarette 
smoking, alcohol intake, physical activity, diabetes history, and insulin use. Chi-square and 
t-tests were used to examine differences in categorical and continuous variables, 
respectively. Differences in dietary and total intake of selected nutrients between cases and 
controls were evaluated with t-tests.
Logistic regression analysis was performed to estimate pancreatic cancer risk in relation to 
the nutrients of interest. Dietary and total intake of folate, vitamin B6, and vitamin B12 as 
well as dietary intake of methionine were each divided into quartiles using cutoff-points 
based on the respective intake data of the controls. Subjects in the lowest (first) quartile for 
each of these dietary variables were treated as the reference group to calculate the odds ratio 
(OR) and 95% confidence interval (CI) for those in the three upper quartiles. Three 
regression models were constructed for each of the nutrients considered. Model 1 was built 
to estimate the crude associations between intake of each of selected nutrients and the risk of 
pancreatic cancer. Adjusted ORs and 95% CIs were calculated for those associations in 
model 2 and model 3. Age (continuous), sex, race (white, black, and other), education (three 
levels), cigarette smoking (never, former, and current), alcohol consumption (serving/week), 
and physical activity (light, moderate, and heavy) were controlled for in model 2. Model 3 
additionally adjusted for intake of energy, fat, fiber, fruits, and vegetables. The 
aforementioned covariates were introduced into models 2 and 3 as established or suspected 
confounders to assess the independent associations between methyl-group availability 
factors and pancreatic cancer risk. The statistical significance of the linear trend across 
quartiles of each of the nutrients examined was tested by assigning a median intake value to 
each quartile and then treating these as values of a continuous variable.
A composite score was created to evaluate the effect of combined dietary intake of folate and 
vitamin B6 on pancreatic cancer due to the shared roles of these two nutrients in DNA 
methylation through the regulation of circulating homocysteine concentrations (23). 
Specifically, 1, 2, 3, and 4 were assigned to subjects in quartiles 1, 2, 3, and 4 of dietary 
folate, respectively. The same method was applied to dietary intake of vitamin B6. The 
composite score for each subject was then calculated by summing a subject’s values 
assigned to those two nutrients; scores ranged from 2 (lowest) to 8 (highest). All statistical 
analyses were performed by using SAS (version 9.4; SAS Institute Inc., Cary, NC). A p-
value of <0.05 (2-sided) was considered statistically significant.
Results
Study subjects were predominantly white, with a mean age of 65.8 years for cases and 66.5 
years for controls. Cases, versus controls, were more likely to be current smokers and 
diagnosed with type-2 diabetes; cases also reported lower levels of education and physical 
activity (Table 1). Cases appeared to have a lower dietary intake of both folate and vitamin 
B6 than controls (folate: 320 vs. 351 μg/day, p=0.041; vitamin B6: 6.17 vs. 9.53 mg/day, 
p=0.084) (Table 2).
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After adjustment for all covariates included in model 3, dietary intake of folate was 
associated with a reduced risk of pancreatic cancer (Table 3). Compared with subjects in the 
first quartile of dietary intake of folate, ORs (95% CIs) for those in the second, third, and 
fourth quartiles were 0.63 (0.35–1.14), 0.77 (0.40–1.49), and 0.31 (0.12–0.78) (p-trend = 
0.036), respectively. A similar inverse association was observed for total intake of folate (i.e. 
folate from both dietary and supplemental sources) [OR (95% CI) for the third vs. the first 
quartile: 0.47 (0.23–0.90)], but this inverse association was not observed when the fourth 
and the first quartiles of total intake of folate were compared. It appeared that total intake of 
vitamin B6 was inversely, and total intake of vitamin B12 was positively, associated with 
pancreatic cancer risk, but these associations were not statistically significant. There are no 
apparent associations between dietary intake of methionine and risk of pancreatic cancer. 
Compared with subjects in the first quartile of the composite score, those in the fourth 
quartile of the score exhibited a 76% reduced risk of pancreatic cancer [OR (95% CI): 0.24 
(0.08–0.70)] (p-trend = 0.024) (Table 4).
As a dietary source of folate and vitamin B6, fruits and vegetables were removed from the 
multivariable regression models to avoid potential overadjustment. The risk estimates 
observed remained materially unchanged after exclusion of these food items. As the number 
of non-whites was very small, the risk estimates obtained were virtually the same when non-
whites were excluded from the analysis.
Discussion
The primary findings of the present analysis were that dietary intake of folate was associated 
with a reduced risk of pancreatic cancer and that a composite score (combined dietary intake 
of folate and vitamin B6) was also inversely associated with pancreatic cancer risk. The tests 
for trend in the adjusted models were statistically significant for dietary folate and the 
composite score.
Our results suggest a potential protective effect of dietary folate intake on pancreatic cancer 
risk and are consistent with results from an analysis of two Swedish cohorts (15) and the 
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study (16). The magnitude of 
the inverse association in our study (OR = 0.31 for 500 vs. 195 μg/day) was similar to the 
Swedish study (RR = 0.25 for >350 vs. <200 μg/day) but somewhat stronger than the ATBC 
study (RR = 0.52 for >373 vs. <280 μg/day). Of note, the validity of the dietary folate results 
observed in the ATBC study were strengthened when analyses were conducted with serum 
folate concentrations from study participants (9).
An inverse association between folate intake and pancreatic cancer risk was not found in the 
Health Professionals Follow-up Study (HPFS), the Nurses’ Health Study (NHS), or a 
combined analysis of 14 cohort studies (17, 24). It should be pointed out that 10 of the 14 
cohorts were conducted among U.S. residents with a high prevalence of multivitamin use 
(e.g. 43% in HPFS and NHS, and 56% in the California Teachers Study). It may be that the 
beneficial effect of folate intake is primarily confined to subjects with a relatively low intake 
of this nutrient, e.g. residents of European countries where the percentage of multivitamin 
use is not high (25–27).
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In the present study, dietary intake of folate was associated with a reduced risk of pancreatic 
cancer, but this inverse association was not observed for total intake of folate. A similar 
difference in the effects of folate from dietary and supplemental sources was reported in the 
ATBC study (16) and the Swedish cohorts (15), although it was not confirmed in a case-
control study in the San Francisco Bay Area (14). The reasons for these discrepant results 
are unclear. One possible explanation is that dietary intake of folate is a better measure of 
long-term exposure to folate rather than recent or irregular use of supplemental folic acid 
and thus is more relevant to the etiology of pancreatic cancer (15).
We found an inverse, though not statistically significant, association of both dietary intake 
and total intake of vitamin B6 with the risk of pancreatic cancer [(OR (95% CI) comparing 
the fourth with the first quartiles: 0.47 (0.19–1.17) and 0.66 (0.34–1.24), respectively). 
Previous studies have yielded mixed results on the effect of vitamin B6 on pancreatic cancer 
(10). Intake of vitamin B6 or levels of its circulating biomarker (pyridoxal-5′-phosphate) 
were associated with a reduced risk of pancreatic cancer in some (9, 18, 28), but not all (14, 
16, 29), studies. A meta-analysis showed that dietary intake of vitamin B6 was significantly 
associated with the risk of pancreatic cancer as well as esophageal, gastric, and colorectal 
cancers [(OR (95% CI) comparing the extreme categories: 0.57 (0.47–0.69) for 
gastrointestinal tract cancers] (10). The specific role of vitamin B6 in pancreatic 
carcinogenesis warrants further investigation. As dietary intakes of both folate and vitamin 
B6 were inversely associated with pancreatic cancer risk in our study, we examined their 
combined effect for the reasons mentioned previously. Our analysis revealed that the 
composite score, derived from intake of these two nutrients, was more strongly associated 
with the risk of this disease than either nutrient alone. This analytic approach has not been 
used in previous studies.
Several lines of experimental evidence provide biochemical mechanisms supporting a role 
for folate and vitamin B6 in pancreatic cancer. The pancreas contains the highest 
concentrations of folate after the liver (30). Folate and vitamin B6 are key nutrients required 
for adequate DNA methylation (11). Abnormal DNA methylation may alter expression of 
proto-oncogenes and tumor suppressor genes (31, 32). The hypermethylation and 
hypomethylation of several dozens of genes have been detected in pancreatic tumor and 
cancer cell lines (12). In addition, folate is also critical for DNA synthesis. Human studies 
have revealed that folate deficiency resulted in misincorporation of uracil into DNA and 
chromosome breakage, and folate supplementation could effectively reduce the occurrence 
of these DNA lesions (33, 34).
Relatively few epidemiological studies have evaluated the associations between intake of 
vitamin B12 and methionine and the risk of pancreatic cancer. Our study did not show any 
significant associations between these two nutrients and the risk of this malignancy, despite 
elevated ORs. Null results for vitamin B12 have been also reported in several other studies 
(16, 18, 28, 35). However, a significantly increased risk associated with vitamin B12 intake 
was found among subjects in the case-control study in the San Francisco Bay Area (14) and 
among people who smoked 20 cigarettes or less per day in the ATBC study (9). An inverse 
association between plasma levels of vitamin B12 and the risk of pancreatic cancer was 
found among Finnish smokers who were non-users of multivitamins and had a median body 
Marley et al. Page 6
Eur J Clin Nutr. Author manuscript; available in PMC 2018 December 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
mass index of <24.7 (ref. 8), but the possibility of chance finding in this Finnish study could 
not be ruled out due to multiple comparisons.
No significant association between methionine intake and pancreatic cancer risk existed in 
the present study, which was consistent with the results of one case-control study (14) and 
three cohort studies (16, 18, 28). A significant inverse association between methionine 
intake and pancreatic cancer risk was observed in a cohort study of Swedish men and 
women (29), but this potential beneficial effect was not replicated in the European 
Prospective Investigation into Cancer and Nutrition in which plasma levels of methionine 
were measured as a biomarker of dietary intake (28).
Our study has several strengths. All cases were identified through a rapid case-ascertainment 
system to avoid proxy interviews that are prone to recall bias. Proxy interviews have been 
used in some case-control studies of pancreatic cancer due to its rapid fatality (36, 37). In 
our study, in-person interviews were performed by trained research staff. To help study 
subjects accurately estimate serving sizes for foods they consumed, food models were used.
Our study has some weaknesses. A response rate of less than 60% was obtained for both 
cases and controls. Such rates have been reported in other case-control studies of pancreatic 
cancer (35, 38–40). Nevertheless, subjects who agreed to participate in the study might be 
different from those who refused with regard to demographic, socioeconomic, and lifestyle 
factors, limiting the generalization of our obtained results. Recall bias is always a concern in 
case-control studies. Recall of dietary habits among cases might have been affected by 
dietary changes in response to clinical symptoms and/or medical treatments of the disease. 
Therefore, reverse causality could not be entirely ruled out for our observed significant 
inverse associations shown in Table 3 and Table 4. The Willett FFQ has been validated 
against dietary record for vitamin B6 (r=0.58, p<0.05) (ref. 41) and against plasma folate 
levels for folate (deattenuated r = 0.54; 95% CI: 0.46–0.61) (ref. 42) but not for vitamin B12. 
Therefore, our reported results would be strengthened if intake of the three vitamins 
examined were validated against their corresponding biomarkers or if these biomarkers were 
evaluated in relation to pancreatic cancer risk. Dietary assessment error derived from the 
FFQ used might have resulted in misclassification of subjects with regard to their dietary 
intake of the nutrients evaluated in the present study. Such misclassification error, if non-
differential, tends to bias risk estimates toward the null. Betaine and choline are also 
nutrients involved in methyl-group metabolism, but were not evaluated in this study due to 
lack of data. Biomarkers, i.e., plasma concentrations of folate, vitamin B6, and vitamin B12, 
were not available in our study. Although body mass index has been associated with 
pancreatic cancer (43), we did not adjust for it in our analysis as subject height and weight 
were not measured due to an oversight. However, the risk estimates reported were controlled 
for both energy intake and physical activity, the two main factors that determine the 
development of overweight and obesity.
In this population-based case-control study, we found that dietary intake of folate and a 
composite score reflective of dietary intake of folate and vitamin B6 were associated with a 
reduced risk of pancreatic cancer. The present study provides additional evidence for the role 
of methyl-related nutrients in the etiology of pancreatic cancer. Our findings need to be 
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confirmed by future studies that not only assess intake of these nutrients, but also measure 
their reliable biochemical indicators among populations with various dietary habits. 
Research in this area is expected to offer novel avenues for the primary prevention and 
control of pancreatic cancer.
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Table 1
Characteristics of cases and controls in a population-based case-control study of pancreatic cancer in 
Minnesota, 1994–1998a
Characteristics Cases (n=150) Controls (n=459) p-value
Age (year) 65.8 (10.9) 66.5 (12.1) 0.13
Sex
 Male 89 (59.3%) 261 (56.9%)
 Female 59 (39.3%) 198 (43.1%)
 Missing 2 (1.3%) 0 (0%) 0.48
Race
 White 137 (91.3%) 450 (98.0%)
 Black 7 (4.7%) 3 (0.7%)
 Other 5 (3.3%) 6 (1.3%)
 Missing 1 (0.7%) 0 (0%) 0.0003
Education
 Some high school or less 25 (16.7%) 56 (12.2%)
 High school graduate 56 (37.3%) 116 (25.3%)
 Some college or more 67 (44.7%) 287 (62.5%)
 Missing 2 (1.3%) 0 (0%) 0.0019
Cigarette Smoking
 Never smoked 57 (38.0%) 215 (46.8%)
 Former smoker 63 (42.0%) 196 (42.7%)
 Current smoker 23 (15.3%) 48 (10.5%)
 Missing 7 (4.7%) 0 (0%) 0.062
Alcohol intake (serving/week) 3.4 (6.9) 4.7 (8.5) 0.065
Physical activity (hour/week)
 Light 23.0 (16.9) 27.1 (16.2) 0.013
 Moderate 15.1 (13.1) 18.1 (12.7) 0.022
 Heavy 5.1 (11.8) 3.9 (5.5) 0.27
 Total 43.3 (27.7) 49.1 (25.4) 0.025
Diabetes history
 Yes 31 (20.7%) 33 (7.2%)
 No 101 (67.3%) 426 (92.8%)
 Unknown/missing 18 (12.0%) 0 (0%) <0.0001
Insulin use
 Yes 13 (8.7%) 13 (2.8%)
 No 12 (8.0%) 20 (4.4%)
 Unknown/missing 125 (83.3%) 426 (92.8%) 0.019
a
Data shown are mean (SD) for continuous variables or n (%) for categorical variables.
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Table 2
Intake of methyl-related nutrients in a population-based case-control study of pancreatic cancer in Minnesota, 
1994–1998
Nutrients Cases (n=150) Controls (n=459) p-value
Mean (SD) Mean (SD)
Dietary folate (μg/day) 320 (170) 351 (155) 0.041
Total folate (μg/day) 470 (299) 497 (277) 0.31
Dietary vitamin B6 (mg/day) 2.24 (1.26) 2.43 (1.09) 0.11
Total vitamin B6 (mg/day) 6.17 (18.5) 9.53 (26.0) 0.084
Dietary vitamin B12 (μg/day) 7.2 (4.9) 7.0 (6.7) 0.77
Total vitamin B12 (μg/day) 12.3 (15.8) 11.0 (13.5) 0.36
Methionine (g/day) 1.88 (0.8) 1.94 (0.9) 0.46
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